A chelate theory for the mechanism of action of aspirin-like drugs

Medical Hypotheses

Volumn 50, Issue 3, 1998, Pages 239-251

  Wang, X ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; METAL CHELATE; METAL ION; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CHELATION; CONFERENCE PAPER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHESIS; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031912242     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90024-X     Document Type: Conference Paper

References (128)

1. Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-235.
2. Davies P, MacIntyre D E. Prostaglandins and inflammation. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 123-138.
3. Ferreira S H, Vane J R. New aspects of the mode of action of nonsteroid anti-inflammatory drugs. Annu Rev Pharmacol 1974; 14: 57-73.
4. Vane J R, Botting R M. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996; 102: 9-21.
5. Weissmann G. Aspirin. Sci Am 1991; 264: 84-90.
6. Mitchell D, Laburn H P, Cooper K E, Hellon R F, Cranston W I, Townsend Y. Is prostaglandin E the neural mediator of the febrile response? The case against a proven obligatory role. Yale J Biol Med 1986; 59: 159-168.
7. Abramson S B, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32: 1-9.
8. Coceani F. Prostaglandins and fever - facts and controversies. In: Mackowiak P, ed. Fever: Basic Mechanisms and Management. New York: Raven Press, 1991: 59-70.
9. Cooper K E. Fever and Antipyresis: The Role of the Nervous System. Cambridge: Cambridge University Press, 1995.
10. Ghooi R B, Thatte S M, Joshi P S. The mechanism of action of aspirin - is there anything beyond cyclo-oxygenase? Med Hypotheses 1995; 44: 77-80.
11. Vane J R. Introduction: mechanism of action of NSAIDs. Br J Rheumatol 1996; 1: 1-3.
12. Langenbach R, Morham S G, Tiano H F et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-492.
13. Morham S G, Langenbach R, Loftin C D et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-482.
14. Dinchuk J E, Car B D, Focht R J et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-409.
15. Szabo S, Bynum T E. Alternatives to the acid-oriented approach to ulcer disease: does 'cytoprotection' exist in man? A new classification of antiulcer agents. Scand J Gastroenterol 1988; 23: 1-6.
16. Wang X. Aspirin-like drugs cause gastrointestinal injuries by metallic cation chelation. Medical Hypotheses 1997; 50: 227-238.
17. Goldstein I M. Agents that interfere with arachidonic acid metabolism. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 1127-1137.
18. Davies C W. The extent of dissociation of salts in water, Part VI: Some calcium salts of organic acids. J Chem Soc 1938; 277-281.
19. Babko A K. Ferro-salicylate complexes. Zhurnal Obshchei Khimii (J Gen Chem) 1945; 15: 745-757.
20. Babko A K. Copper salicylate complexes. Zhurnal Obshchei Khimii (J Gen Chem) 1947; 17: 443-449.
21. Foley R T, Anderson R C. Spectrophotometric studies on complex formation with sulfosalicylic acid, I: With iron (III). J Am Chem Soc 1949; 70: 1195-1197.
22. Turner S E, Anderson R C. Spectrophotometric studies of complex formation with sulfosalicylic acid, III: With copper (II). J Am Chem Soc 1949; 71: 912-914.
23. Banks C V, Patterson J H. A polarographic investigation of iron-sulfosalicylate complex ions. J Am Chem Soc 1951; 73: 3062-3064.
24. Agren A. The complex formation between iron (III) ion and some phenols, II: Salicylic acid and p-aminosalicylic acid. Acta Chem Scand 1954; 8: 1059-1072.
25. Vareille L. Ferriphenolic complexes, II: Ferrisulfosalicylic complexes. Bull Soc Chim France 1955; 872-877.
26. Baker W. Abnormal strength of 2:6-dihydroxybenzoic acids. Nature 1936; 137: 236.
27. Mills R F, Adams S S, Cliffe E E, Dickinson W, Nicholson J S. The metabolism of ibuprofen. Xenobiotica 1973; 3: 589-598.
28. Flower R J, Moncada S, Vane J R. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman A G, Goodman L S, Rail T W, Murad F, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan, 1985: 674-715.
29. Northover A M. The effects of some non-steroidal anti-inflammatory agents on membrane-associated calcium in rabbit peritoneal neutrophils. Biochem Pharmacol 1985; 34: 3123-3129.
30. Pharmacopeia, 13th edn. Easton, PA: Mack, 1947.
31. McEvoy G K, ed. Nonsteroidal anti-inflammatory agents. Bethesda, MD: American Society of Health-System Pharmacists, 1996.
32. Loll P J, Picot D, Garavito R M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct Biol 1995; 2: 637-643.
33. Vane J R, Flower R J, Botting R M. History of aspirin and its mechanism of action. Stroke 1990; 21: IV12-23.
34. Collier H O. A pharmacological analysis of aspirin. Adv Pharmacol Chemother 1969; 7: 333-405.
35. Clapham D E. Calcium signaling. Cell 1995; 80: 259-268.
36. Welch S P, Thomas C, Patrick G S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995; 272: 310-321.
37. Smith F L, Stevens D L. Calcium modulation of morphine analgesia: role of calcium channels and intracellular pool calcium. J Pharmacol Exp Ther 1995; 272: 290-299.
38. Braga P C. Calcitonin and its antinociceptive activity: animal and human investigations 1975-1992. Agents Actions 1994; 41: 121-131.
39. Braga P C, Dal Sasso M, Bernini A, Bartucci F, Pollo A, Carbone E. Antinociceptive activity of salmon calcitonin: electrophysiological correlates in a rat chronic pain model. Neurosci Lett 1993; 151: 85-88.
40. Barbosa L M, Gauthier V J, Davis C L. Bone pain that responds to calcium channel blockers: a retrospective and prospective study of transplant recipients. Transplantation 1995; 59: 541-544.
41. Celik A F, Katsinelos P, Read N W, Khan M I, Donnelly T C. Hereditary proctalgia fugax and constipation: report of a second family. Gut 1995; 36: 581-584.
42. Gedalia I, Brayer L, Kalter N, Richter M, Stabholz A. The effect of fluoride and strontium application on dentin: in vivo and in vitro studies. J Periodontol 1978; 49: 269-272.
43. Robinson R G. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993; 72: 3433-3435.
44. Welch S P, Vocci F J, Jr, Dewey W L. Antinociceptive and lethal effects of intraventricularly administered barium and strontium: antagonism by atropine sulfate or naloxone hydrochlorine. Life Sci 1983; 33: 359-364.
45. Xiao W H, Bennett G J. Magnesium suppresses neuropathic pain responses in rats via a spinal site of action. Brain Res 1994; 666: 168-172.
46. Xiao W H, Bennett G J. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 1995; 274: 666-672.
47. 2+ channels. Neuroscience 1994; 61: 191-197.
48. Chaplan S R, Pogrel J W, Yaksh T L. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994; 269: 1117-1123.
49. Myers R D, Tytell M. Fever: reciprocal shift in brain sodium to calcium ratio as the set-point temperature rises. Science 1972; 178: 765-767.
50. Palmi M, Frosini M, Sgaragli G. Calcium changes in rabbit CSF during endotoxin, IL-1 beta, and PGE2 fever. Pharmacol Biochem Behav 1992; 43: 1253-1262.
51. Stitt J T, Shimada S G. Calcium channel blockers inhibit endogenous pyrogen fever in rats and rabbits. J Appl Physiol 1991; 71: 951-955.
52. Szreder Z, Korolkiewicz Z. Inhibition of pyrogen Escherichia coli fever with intracerebral administration of prazosin, dihydrobenzperidol and nifedipin in the rabbits. Gen Pharmacol 1991; 22: 381-388.
53. Guyton A C, Hall J E. Textbook of Medical Physiology, 9th edn. Philadelphia: W. B. Saunders, 1996.
54. Stitt J T. Fever versus hyperthermia. Fed Proc 1979; 38: 39-43.
55. Graener R, Werner J. Dynamics of endotoxin fever in the rabbit. J Appl Physiol 1986; 60: 1504-1510.
56. Baracos V E, Whitmore W T, Gale R. The metabolic cost of fever. Can J Physiol Pharmacol 1987; 65: 1248-1254.
57. Stettler N, Schutz Y, Whitehead R, Jequier E. Effect of malaria and fever on energy metabolism in Gambian children. Pediatr Res 1992; 31: 102-106.
58. Fewell J E, Ricciuti F, Kondo C S, Dascalu V. Fever in young lambs: temperature, metabolic and cardiorespiratory responses to a small dose of bacterial pyrogen. J Dev Physiol 1991; 15: 229-235.
59. Himms-Hagen J. Cellular thermogenesis. Annu Rev Physiol 1976; 38: 315-351.
60. Tanaka J, Kono Y, Shimahara Y et al. A study of oxidative phosphorylative activity and calcium-induced respiration of rat liver mitochondria following living Escherichia coli injection. Adv Shock Res 1982; 7: 77-90.
61. Akhtar R A, Perry M C. Insulin action in isolated fat cells, II: Effects of divalent cations on stimulation by insulin of protein synthesis, on inhibition of lipolysis by insulin, and on the binding of 1251-labelled insulin to isolated fat cells. Biochim Biophys Acta 1979; 585: 117-127.
62. Garfinkel D, Garfmkel L. Magnesium and regulation of carbohydrate metabolism at the molecular level. Magnesium 1988; 7: 249-261.
63. Brand I A, Kleineke J. Intracellular zinc movement and its effect on the carbohydrate metabolism of isolated rat hepatocytes. J Biol Chem 1996; 271: 1941-1949.
64. Atkins E, Bodel P. Clinical fever: its history, manifestations and pathogenesis. Fed Proc 1979; 38: 57-63.
65. Hogaboam C M, Bissonnette E Y, Chin B C, Befus A D, Wallace J L. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 1993; 104: 122-129.
66. Wallace J L, Tigley A W. Review article: new insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther 1995; 9: 227-235.
67. Weissmann G, Vosshall L B, Bayer C A, Dunham P B. Marine sponge aggregation: a model for effects of NSAIDs on the calcium movements of cell activation. Semin Arthritis Rheum 1985; 15: 42-53.
68. Atkinson T P, White M V, Kaliner M A. Histamine and serotonin. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 193-209.
69. Unkeless J C, Boros P, Fein M. Structure, signaling, and function of FcgammaR. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 497-510.
70. Hostoffer R W, Krukovets I, Berger M. Increased Fc alpha R expression and IgA-mediated function on neutrophils induced by chemoattractants. J Immunol 1993; 150: 4532-4540.
71. Prpic V, Uhing R J, Weiel J E et al. Biochemical and functional responses stimulated by platelet-activating factor in murine peritoneal macrophages [published erratum appears in J Cell Biol 1988 Sep; 107(3): following 1260]. J Cell Biol 1988; 107: 363-372.
72. Adams D O. Molecular interactions in macrophage activation. Immunol Today 1989; 10: 33-35.
73. Pruimboom W M, van Dijk A P, Tak C J, Zijlstra F J, Bonta I L, Wilson J H. Inflammatory mediators and activity of human peritoneal macrophages. Agents Actions 1993; 38: C86-88.
74. Butenko I G, Gladtchenko S V, Galushko S V. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis georgy roots. Agents Actions 1993; 39: C49-51.
75. Snyderman R, Uhing R J. Chemoattractant stimulus-response coupling. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 421-439.
76. Henson P M, Henson J E, Fittschen C, Bratton D L, H. R D W. Degranulation and secretion by phagocytic cells. In: Gallin J I, Goldstern I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 511-539.
77. Zimmerman G A, Prescott S M, McIntyre T M. Platelet-activating factor: a fluid-phase and cell-associated mediator of inflammation. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992; 149-176.
78. Kishimoto T K, Anderson D C. The role of integrins in inflammation. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 353-406.
79. Herberman R B. Cytotoxic activities of lymphocytes. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 791-807.
80. Paul W E. Development and function of lymphocytes. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2 edn. New York: Raven Press, 1992: 775-790.
81. De Vries G W, McLaughlin A, Wenzel M B et al. The anti-inflammatory activity of topically applied novel calcium-channel antagonists. Inflammation 1995; 19: 261-275.
82. Briukhanov V M, Zverev Ia F, Elkin V I. [The effect of calcium antagonists on the development of inflammatory edema in rats]. Eksp Klin Farmakol 1994; 57: 47-49.
83. Hackshaw K V. Shi Y. Fihroblast growth factor mobilize peritoneal macrophage intracellular calcium. Life Sci 1994; 54: 661-670.
84. Klaassen C D. Heavy metals and heavy-metal antagonists. In: Gilman A G, Goodman L S, Rail T W, Murad F, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan, 1985: 1605-1627.
85. Roberts N A, Tong B P. Histidine analogues as potential novel antirheumatic agents. Drug Des Deliv 1986; 1: 113-118.
86. Hewitt S D, Hider R C, Sarpong P, Morris C J, Blake D R. Investigation of the anti-inflammatory properties of hydroxy-pyridinones. Ann Rheum Dis 1989; 48: 382-388.
87. Weinberg K. Novel uses of deferoxamine. Am J Pediatr Hematol Oncol 1990; 12: 9-13.
88. Schmitz G, Lepper H, Estler C J. Failure of calcium antagonistic agents to prevent hepatotoxicity induced by diclofenac. Pharmacol Toxicol 1995; 77: 32-35.
89. Hennekens C H, Buring J E. Aspirin in the primary prevention of cardiovascular disease. Cardiol Clin 1994; 12: 443-450.
90. Willis A L. An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science 1974; 183: 325-327.
91. Marcus A J, Safier L B, Broekman M J et al. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 1995; 74: 213-217.
92. Szczeklik A. Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Thromb Haemost 1995; 74: 77-80.
93. Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
94. Fabiani J N, Bunting S, Terrier E et al. [Clinical study of prostacyclin in extracorporeal circulation: effects on hemodynamics and coagulation]. Arch Mal Coeur Vaiss 1982; 75: 241-248.
95. Weksler B B. Platelets. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 727-746.
96. Trang L E. Prostaglandins and inflammation. Semin Arthritis Rheum 1980; 9: 153-190.
97. Davie E W. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
98. McVey J H. Tissue factor pathway. Baillieres Clin Haematol 1994; 7: 469-484.
99. O'Reilly R A. Anticoagulant, antithrombotic, and thrombolytic drugs. In: Gilman A G, Goodman L S, Rail T W, Murad F, eds. The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan, 1985: 1338-1359.
100. Heath C W, Jr, Thun M J, Greenberg E R, Levin B, Marnett L J. Nonsteroidal antiinflammatory drugs and human cancer: report of an interdisciplinary research workshop. Cancer 1994; 74: 2885-2888.
101. Macilwain C. Aspirin on trial as HIV treatment [news; comment]. Nature 1993; 364: 369.
102. Disla E, Rhim H R, Reddy A, Taranta A. Improvement in CD4 lymphocyte count in HIV-Reiter's syndrome after treatment with sulfasalazine. J Rheumatol 1994; 21: 662-664.
103. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol Suppl 1996; 102: 3-8.
104. Deykin D. Emerging concepts of platelet function. N Engl J Med 1974; 290: 144-151.
105. Greger R. In: Greger R, Windhorst U, eds. Comprehensive Human Physiology. Berlin, Heidelberg: Springer-Verlag, 1996: 1489-1516.
106. Yang F Y, Huang Y G, Tu Y P. Divalent cation and lipid-protein interactions of biomembranes. Biosci Rep 1993; 13: 143-157.
107. Lehninger A L. Oxidation-reduction enzymes and electron transport. In: Biochemistry, 2nd edn. New York: Worth, 1975: 477-508.
108. Darnell J, Lodish H, Baltimore D. The plasma membrane. In: Molecular Cell Biology, 2nd edn. New York: Scientific American Books/W H Freeman, 1990: 491-530.
109. Zenner H-P. In: Greger R, Windhorst U, eds. Comprehensive Human Physiology. Berlin, Heidelberg: Springer-Verlag 1996: 711-727.
110. Thompson H J, Briggs S, Paranka N S et al. Inhibition O: mammary carcinogenesis in rats by sulfone metabolite O: sulindac. J Natl Cancer Inst 1995; 87: 1259-1260.
111. Hanif R, Pittas A, Feng Y et al. Effects of nonsteroida anti-inflammatory drugs on proliferation and on inductioi of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
112. Goldberg Y. Aspirin and colon cancer [letter]. N Engl J Med 1996; 334: 800-801.
113. Durham A C, Walton J M. Calcium ions and the control of proliferation in normal and cancer cells. Biosci Rep 1982; 2: 15-30.
114. Goldberg Y, Nassif I I, Pittas A et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12: 893-901.
115. Shiff S J, Koutsos M I, Qiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-188.
116. Tsuruo T, Naito M, Takamori R et al. A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors. Cancer Chemother Pharmacol 1990; 26: 83-87.
117. Zacharski L R, Moritz T E, Haakenson C M et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest 1990; 8: 451-458.
118. Wargovich M J, Baer A R. Basic and clinical investigations of dietary calcium in the prevention of colorectal cancer. Prev Med 1989; 18: 672-679.
119. McConkey D J, Orrenius S. The role of calcium in the regulation of apoptosis. J Leukoc Biol 1996; 59: 775-783.
120. Robert A. Cytoprotection of the gastrointestinal mucosa. Adv Intern Med 1983; 28: 325-337.
121. Vink C, Lutzke R A, Plasterk R H. Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA. Nucleic Acids Res 1994; 22: 4103-4110.
122. Ellison V, Brown P O. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci USA 1994; 91: 7316-7320.
123. Pemberton I K, Buckle M, Buc H. The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II). J Biol Chem 1996; 271: 1498-1506.
124. Wolfe A L, Felock P J, Hastings J C, Blau C U, Hazuda D J. The role of manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 integrase as a catalytically active complex on immobilized long terminal repeat substrates. J Virol 1996; 70: 1424-1432.
125. Ktistakis N T, Kao C Y, Lang D. In vitro assembly of the outer shell of bacteriophage phi 6 nucleocapsid [published erratum appears in Virology 1989; 169(1): 248]. Virology 1988; 166: 91-102.
126. Shirley J A, Beards G M, Thouless M E, Flewett T H. The influence of divalent cations on the stability of human rotavirus. Arch Virol 1981; 67: 1-9.
127. 4 on the thermostability of viruses. Virology 1965; 26: 694-699.
128. Lam B K, Austen K F. Leukotrienes: biosynthesis, release, and actions. In: Gallin J I, Goldstein I M, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York: Raven Press, 1992: 139-147.